We present a 74-year-old man with a history of very high-risk prostate cancer (Gleason score: 5+4 in 11 of 14 cores) who was referred for initial staging with 99mTc-HYNIC-PSMA. The scan was reported as miT2m N2(REI, ROB) M1b(uni) M1c(skin?), PRIMARY score: 4, PSMA expression score: 1-3. We incidentally discovered increased uptake in the left skull region on whole-body images. Subsequent SPECT/CT imaging localized this uptake to a subcutaneous nodule in the scalp, which pathologic analysis confirmed to be a neurofibroma. Several lesions of neurological origin may exhibit significant PSMA avidity, which is reviewed here.

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000005797DOI Listing

Publication Analysis

Top Keywords

99mtc-psma uptake
4
uptake neurofibroma
4
neurofibroma 74-year-old
4
74-year-old man
4
man history
4
history high-risk
4
high-risk prostate
4
prostate cancer
4
cancer gleason
4
gleason score
4

Similar Publications

We present a 74-year-old man with a history of very high-risk prostate cancer (Gleason score: 5+4 in 11 of 14 cores) who was referred for initial staging with 99mTc-HYNIC-PSMA. The scan was reported as miT2m N2(REI, ROB) M1b(uni) M1c(skin?), PRIMARY score: 4, PSMA expression score: 1-3. We incidentally discovered increased uptake in the left skull region on whole-body images.

View Article and Find Full Text PDF

We present a case of a 69-year-old man diagnosed with prostate adenocarcinoma, who underwent 99mTc-PSMA scintigraphy as part of his initial staging workup. The scan revealed a focal uptake in the posterior abdominal wall, corresponding to a subcutaneous soft tissue lesion. Further evaluation using SPECT/CT imaging localized the lesion, which was subsequently excised and histopathologically diagnosed as an angiolipoma.

View Article and Find Full Text PDF

This case report presents a rare instance of pulmonary lymphangitic carcinomatosis (PLC) in a prostate cancer patient, showcasing uptake of 99mTc-prostate-specific membrane antigen and 99mTc-fibroblast activation protein inhibitor-46 on imaging scans. A 70-year-old man with elevated serum prostate-specific antigen (PSA) levels exhibited respiratory symptoms and was diagnosed with widespread skeletal and pulmonary metastases. Following taxane-based chemotherapy and androgen deprivation therapy, imaging revealed decreased uptake and improvement in clinical symptoms, indicating treatment response.

View Article and Find Full Text PDF

Association between 99mTc-PSMA SPECT/CT imaging and prostate-specific antigen (PSA) and alkaline phosphatase (ALP) levels post-endocrine therapy in patients with prostate cancer and bone metastases.

Rev Esp Med Nucl Imagen Mol (Engl Ed)

November 2024

Department of Nuclear Medicine, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou 450003, China. Electronic address:

Aim: To investigate the association between positive lesions detected by 99mTc-PSMA SPECT/CT and blood levels of prostate-specific antigen (PSA) and alkaline phosphatase (ALP) in patients with prostate cancer (PCa) and bone metastasis undergoing endocrine therapy.

Methods: A retrospective analysis was performed on 43 patients diagnosed with PCa bone metastasis who underwent endocrine therapy. PSA, ALP, whole body bone imaging and 99mTc-PSMA SPECT/CT imaging were collected from all patients (Among them, 17 cases were re-examined 99mTc-PSMA SPECT/CT imaging).

View Article and Find Full Text PDF

Background: PSMA PET/CT is the most sensitive molecular imaging modality for prostate cancer (PCa), yet much of the developing world has little or no access to PET/CT. [Tc]Tc-PSMA scintigraphy (PS) is a cheaper and more accessible gamma camera-based alternative. However, many resource-constrained departments have only a single camera without tomographic or hybrid imaging functionality, and camera time is frequently in high demand.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!